BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 24510347)

  • 1. The diagnostic and prognostic value of serum human kallikrein-related peptidases 11 in non-small cell lung cancer.
    Xu CH; Zhang Y; Yu LK
    Tumour Biol; 2014 Jun; 35(6):5199-203. PubMed ID: 24510347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum Cripto-1 is a novel biomarker for non-small cell lung cancer diagnosis and prognosis.
    Xu CH; Wang Y; Qian LH; Yu LK; Zhang XW; Wang QB
    Clin Respir J; 2017 Nov; 11(6):765-771. PubMed ID: 26605871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic and prognostic value of serum Cripto-1 in patients with non-small cell lung cancer.
    Xu CH; Chi CZ; Zhang Q; Wang YC; Wang W; Yuan Q; Zhan P; Zhang XW; Lin Y
    Clin Respir J; 2018 Oct; 12(10):2469-2474. PubMed ID: 29570945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic and prognostic value of serum periostin in patients with non-small cell lung cancer.
    Xu CH; Wang W; Lin Y; Qian LH; Zhang XW; Wang QB; Yu LK
    Oncotarget; 2017 Mar; 8(12):18746-18753. PubMed ID: 27816968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic and prognostic value of serum thioredoxin and DJ-1 in non-small cell lung carcinoma patients.
    Fan J; Yu H; Lv Y; Yin L
    Tumour Biol; 2016 Feb; 37(2):1949-58. PubMed ID: 26334622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of serum sMICA levels in non-small cell lung cancer.
    Wang LP; Niu H; Xia YF; Han YL; Niu P; Wang HY; Zhou QL
    Eur Rev Med Pharmacol Sci; 2015 Jun; 19(12):2226-30. PubMed ID: 26166647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multiparametric serum kallikrein panel for diagnosis of non-small cell lung carcinoma.
    Planque C; Li L; Zheng Y; Soosaipillai A; Reckamp K; Chia D; Diamandis EP; Goodglick L
    Clin Cancer Res; 2008 Mar; 14(5):1355-62. PubMed ID: 18316555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum level of DKK-1 and its prognostic potential in non-small cell lung cancer.
    Dong LL; Qu LY; Chu LY; Zhang XH; Liu YH
    Diagn Pathol; 2014 Mar; 9():52. PubMed ID: 24612589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic and Prognostic Value of Serum Angiopoietin-Like Protein 2 in Patients with Non-Small Cell Lung Cancer.
    Chen Y; Jiang H; Zhu L; Wang P; Liu S; Xiao X; Yu H; Dong W
    Clin Lab; 2017 Jan; 63(1):59-65. PubMed ID: 28164488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum macrophage inhibitory cytokine-1 as a clinical marker for non-small cell lung cancer.
    Xu C; Li L; Wang W; Zhang Q; Zhang X; Yang R
    J Cell Mol Med; 2021 Mar; 25(6):3169-3172. PubMed ID: 33605059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum levels of the cancer-testis antigen POTEE and its clinical significance in non-small-cell lung cancer.
    Wang Q; Li X; Ren S; Cheng N; Zhao M; Zhang Y; Li J; Cai W; Zhao C; Cao W; Zhou C
    PLoS One; 2015; 10(4):e0122792. PubMed ID: 25860145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum interleukin-17 as a diagnostic and prognostic marker for non-small cell lung cancer.
    Xu C; Hao K; Yu L; Zhang X
    Biomarkers; 2014 Jun; 19(4):287-90. PubMed ID: 24731052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A laboratory prognostic index model for patients with advanced non-small cell lung cancer.
    Ulas A; Turkoz FP; Silay K; Tokluoglu S; Avci N; Oksuzoglu B; Alkis N
    PLoS One; 2014; 9(12):e114471. PubMed ID: 25474743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of serum miR-411 as a diagnosis and prognosis biomarker for non-small cell lung cancer.
    Wang SY; Li Y; Jiang YS; Li RZ
    Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4092-4097. PubMed ID: 29028091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative serum LMTK3 as a novel biomarker in non-small cell lung cancer.
    Xu Z; Qi X; Zhang X; Yu L
    Tumour Biol; 2014 May; 35(5):5007-11. PubMed ID: 24510346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between Glasgow Prognostic Score and serum tumor markers in patients with advanced non-small cell lung cancer.
    Jiang AG; Chen HL; Lu HY
    BMC Cancer; 2015 May; 15():386. PubMed ID: 25956656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC-A retrospective cohort study.
    Lang D; Horner A; Brehm E; Akbari K; Hergan B; Langer K; Asel C; Scala M; Kaiser B; Lamprecht B
    Lung Cancer; 2019 Aug; 134():59-65. PubMed ID: 31319996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of serum chemerin levels in patients with non-small cell lung cancer.
    Xu CH; Yang Y; Wang YC; Yan J; Qian LH
    Oncotarget; 2017 Apr; 8(14):22483-22489. PubMed ID: 28160556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ELMO3 is a novel biomarker for diagnosis and prognosis of non-small cell lung cancer.
    Fan W; Yang H; Xue H; Sun Y; Zhang J
    Int J Clin Exp Pathol; 2015; 8(5):5503-8. PubMed ID: 26191257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic and prognostic values of endothelial-cell-specific molecule-1 with malignant pleural effusions in patients with non-small cell lung cancer.
    Lu GJ; Shao CJ; Zhang Y; Wei YY; Xie WP; Kong H
    Oncotarget; 2017 Jul; 8(30):49217-49223. PubMed ID: 28514746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.